Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF‐κB p65 Driven Inflammation
Advanced Science · 2025-09 · 12 (33)
DOI: 10.1002/advs.202503325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.06.2025. Verfasst von Lu'an Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510…. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Foundation and application foundation research project of Guangdong Province, Guangzhou Basic Research and Applied Basic Research Program.
Abstract (Originalsprache)
Receptor‐interacting protein kinase 3 (RIPK3) is a key player in necroptosis and an emerging inflammation regulator, whose contribution to podocyte injury in diabetic kidney disease (DKD) remain unclear. Here, podocyte‐specific RIPK3‐knockout (KO) DKD mice and high glucose (HG) cultured mouse podocytes are used to elucidate the protective effects of podocyte RIPK3 deletion on DKD, explore the molecular pathogenic mechanisms of RIPK3 in podocyte injury, and assess pharmacological inhibition of RIPK3 signaling as a therapeutic strategy. The results demonstrated that podocyte‐specific RIPK3‐KO alleviated albuminuria, mesangial matrix proliferation, foot process fusion, and podocyte loss in DKD mice. Additionally, podocyte RIPK3 is upregulated in renal biopsies with DKD and expression is negatively correlated with albuminuria. In vitro, knockdown of RIPK3 using small interfering RNA (siRNA) or inhibition with GSK'872 prevented podocyte injury. RNA sequencing of mouse podocytes revealed that the knockdown of RIPK3 can alleviate HG‐induced activation of the NF‐κB‐related inflammatory pathways. Importantly, pharmacological inhibition of RIPK3 by GSK'872 alleviated podocyte damage, and reduced proteinuria in DKD mice. Overall, these results uncovered a novel role of podocyte RIPK3 in promoting podocyte injury and DKD progression by regulating NF‐κB‐mediated inflammatory signaling independent of necroptosis, offering novel insights and potential therapeutic strategies for DKD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
ORCID-Profile: Xinling Liang
Förderung
- National Natural Science Foundation of China
- Foundation and application foundation research project of Guangdong Province
- Guangzhou Basic Research and Applied Basic Research Program
- Guangdong-Hong Kong Joint Laboratory on Immunological and Genetic Kidney Diseases
Zitieren
APA
Li, L., Li, J., Li, R., Zhao, X., Chen, Y., Cai, Y., Yang, Y., Wang, W., Zheng, S., Zhang, L., & Liang, X. (2025). Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF‐κB p65 Driven Inflammation. Advanced Science, 12(33). https://doi.org/10.1002/advs.202503325
Vancouver
Li L, Li J, Li R, Zhao X, Chen Y, Cai Y, et al. Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF‐κB p65 Driven Inflammation. Advanced Science. 2025;12(33). doi:10.1002/advs.202503325
BibTeX
@article{Li2025,
author = {Li, Lu'an and Li, Jiaying and Li, Ruizhao and Zhao, Xingchen and Chen, Yuanhan and Cai, Yating and Yang, Yan and Wang, Weiteng and Zheng, Siqi and Zhang, Li and Liang, Xinling},
title = {Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF‐κB p65 Driven Inflammation},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {33},
doi = {10.1002/advs.202503325}
}
EUVIMED